<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01501383</url>
  </required_header>
  <id_info>
    <org_study_id>VX11-765-402</org_study_id>
    <nct_id>NCT01501383</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy</brief_title>
  <official_title>A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy With a 24-Week Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and tolerability of VX-765 in
      subjects with treatment-resistant partial epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated by Sponsor
  </why_stopped>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction in weekly seizure frequency during the Part A Late Treatment Period compared to the Part A Baseline Period</measure>
    <time_frame>Up to 25 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of subjects with 50% or greater reduction in weekly seizure frequency (responder-rate) during the Part A Late Treatment Period compared to the Part A Baseline Period</measure>
    <time_frame>Up to 25 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by vital signs, standard 12-lead electrocardiograms (ECGs), laboratory assessments (serum chemistry, hematology, and urinalysis), and adverse events</measure>
    <time_frame>Up to 56 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as determined by vital signs, standard 12-lead electrocardiograms (ECGs), laboratory assessments (serum chemistry, hematology, and urinalysis) and adverse events</measure>
    <time_frame>Up to 56 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects who are seizure-free during the Part A Late Treatment Period</measure>
    <time_frame>Up to 25 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in seizure frequency during the entire Part A Treatment Period compared to the Part A Baseline Period</measure>
    <time_frame>Up to 25 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with 50% or greater reduction in seizure frequency (responder-rate) during the entire Part A Treatment Period compared to the Part A Baseline Period</measure>
    <time_frame>Up to 25 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects who are seizure-free during the entire Part A Treatment Period</measure>
    <time_frame>13 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum number of consecutive days that subjects do not have seizures at any time during the Part A Late Treatment Period</measure>
    <time_frame>Up to 13 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum number of consecutive days that subjects do not have seizures at any time during the entire Treatment Period</measure>
    <time_frame>13 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (e.g AUC, Cmax) of VX-765, VRT-043198, and concomitant antiepileptic drug (AED) levels in blood</measure>
    <time_frame>Up to 21 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in weekly seizure frequency compared to the Part A Baseline Period</measure>
    <time_frame>Up to 56 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with 50% or greater reduction in weekly seizure frequency (50% responder-rate) during the entire Part B Treatment Period compared to the Part A Baseline Period</measure>
    <time_frame>Up to 56 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with 75% or greater reduction in weekly seizure frequency (75% responder-rate) during the entire Part B Treatment Period compared to the Part A Baseline Period</measure>
    <time_frame>Up to 56 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects who are seizure-free during the entire Part B Treatment Period</measure>
    <time_frame>Up to 28 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum number of consecutive days that subjects do not have seizures at any time during the entire Part B Treatment Period</measure>
    <time_frame>Up to 28 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent increase in weekly seizure-free days compared to the Part A Baseline Period</measure>
    <time_frame>Up to 56 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>VX-765 Dose 1 Part A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VX-765 Dose 2 Part A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VX-765 Dose 3 Part A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VX-765 Dose 4 Part A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dose Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VX-765 Dose Part B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-765 Part A</intervention_name>
    <description>Tablets of VX-765 given at different doses based on treatment group in Part A</description>
    <arm_group_label>VX-765 Dose 1 Part A</arm_group_label>
    <arm_group_label>VX-765 Dose 2 Part A</arm_group_label>
    <arm_group_label>VX-765 Dose 3 Part A</arm_group_label>
    <arm_group_label>VX-765 Dose 4 Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo Dose Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-765 Part B</intervention_name>
    <description>Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B</description>
    <arm_group_label>VX-765 Dose Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part A and Part B Inclusion Criteria:

          -  Males or females aged 18 to 64 years with a body mass index between 18 and 35 (kg/m2)

          -  Subjects who have completed the assigned study treatment in Part A may enter Part B if
             eligible per protocol

          -  Male or female subjects must agree to use acceptable contraceptive methods, as
             described in the protocol

          -  Must have a diagnosis and history of treatment-resistant partial-onset epilepsy for
             which they are taking 1 to 4 concomitant AEDs at the time of Screening Period

          -  Have had at least 1 electroencephalogram consistent with partial epilepsy

          -  Must have had at least 6 partial-onset seizures and a seizure-free period of no more
             than 3 weeks (21 days) during the Baseline Period.

          -  Subjects with stable medical conditions (e.g., cannot have a condition that will
             interfere with the conduct of the study or cause a known increase in risk of the
             intervention) as determined by the principal investigator

          -  Must be able and willing to provide written informed consent to participate

          -  Must be able to understand and comply with protocol requirements and instructions

        Part A and Part B Exclusion Criteria:

          -  Subjects who are male and their female partner (if of childbearing potential) does not
             agree to use medically approved methods of contraception as described in the protocol
             for the duration od the study and for 90 days after last dose of study drug

          -  Subjects who are male and have a female partner who is pregnant, nursing, or is
             planning to become pregnant during the study period, or within 90 days of the last
             dose of study drug.

          -  Subjects who are pregnant or lactating, or who are of reproductive potential who do
             not agree to use medically approved birth control methods

          -  History of nonepileptic, transient alterations in consciousness

          -  History of status epilepticus in the past 12 months before the screening visit

          -  Subjects whose seizure frequency cannot be quantified (i.e. seizures with no discrete
             beginning or end, or period between seizures)

          -  Subjects who have a significant medical illness including kidney, liver, pulmonary, or
             gastrointestinal disease; or unstable or poorly controlled conditions such as
             hypertension, diabetes, or angina pectoris, as judged by the investigator.

          -  Have a clinically significant psychiatric illness as judged by the investigator

          -  Subjects who have had an active suicidal plan/intent or active suicidal thoughts, or
             suicide attempt as defined in the protocol

          -  Clinically significant laboratory abnormalities during the Screening Visit/Baseline
             Period, as judged by the investigator

          -  Subjects who have had serious adverse events (SAEs) thought to be related to study
             drug that led to discontinuation during Part A may not participate in Part B

          -  Active hepatitis B, hepatitis C, or human immunodeficiency virus

          -  Positive drug screen at screening or during the Baseline Period (excluding any allowed
             prescribed medications) and/or a history of alcoholism or drug addiction within past 2
             years

          -  Subjects on felbamate with fewer than 18 month of continuous felbamate exposure at the
             time of the Screening Visit or with significant adverse reactions to felbamate

          -  Subjects treated with vigabatrin fewer than 2 years prior to the Screening Visit or
             who have a prior history of treatment with vigabatrin without a documented stable
             examination by an ophthalmologist as defined in the protocol

          -  Using prohibited medications or treated with any systemic immunosuppressant

          -  Have experienced a symptomatic viral, fungal, or bacterial infection requiring
             systemic treatment within 7 days prior to the first dose of study drug

          -  A current or prior history of illness precluding them from immunomodulatory therapy
             (e.g., history of recurrent infections)

          -  Have donated any blood or have had a significant loss of blood (500 mL) as defined in
             the protocol

          -  Have participated in any other clinical studies involving an investigational product
             or device and have received the last dose of the study drug associated with that
             clinical study within 30 days or 5 half-lives (whichever is longer) of the Screening
             Visit

          -  Have participated in earlier VX-765 clinical studies and received at least one dose of
             study drug

          -  Subjects who have no completed the full 13-week Treatment Period in part A may not
             participate in Part B

          -  Any subject judged by the investigator, sponsor or designee to be inappropriate for
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alabama</name>
      <address>
        <city>Northport</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizon</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota</name>
      <address>
        <city>St Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia</name>
      <address>
        <city>Charlotesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Germany</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Germany</name>
      <address>
        <city>Kork</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>January 15, 2014</last_update_submitted>
  <last_update_submitted_qc>January 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

